Business
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November ...
About this update from Evotec Se
[{"type":"list","items":[{"val":[{"type":"text","content":"Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec","length":80,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":205,"olType":false},{"type":"text","content":"HAMBURG, DE / ACCESS Newswire / November 12, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that it has received a US$ 5 m milestone payment from Bristol Myers Squibb, following the acceptance of an Investigational New Drug ("IND") application by the U.S. Food and Drug Administration ("FDA") in their strategic protein degradation partnership. The drug candidate, a cereblon E3 ligase modulator ("CELMoD™") was developed under the collaboration, and a Phase 1 clinical trial is expected to begin in 2026.","length":626,"tagName":"p"},{"type":"text","content":"Initiated in 2018, the collaboration combines Evotec's high-performance multi-omics screening as well as AI-supported data analytics and drug design capabilities with Bristol Myers Squibb's industry-leading library of CELMoDs™. The collaboration, expanded in 2022, continues to deliver on its goal to identify novel molecular glue degraders for high-value targets in the field of oncology and beyond.","length":408,"tagName":"p"},{"type":"text","content":"Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to have reached this important achievement in our collaboration with Bristol Myers Squibb, and to move one step closer to bringing the first compound of our molecular glue degrader pipeline to the clinic. This IND acceptance represents not only a major scientific and regulatory milestone but also validates the strength of our collaboration and emphasizes the enormous potential for delivering multiple first-in-class products to market."","length":530,"tagName":"p"},{"type":"text","content":"About molecular glue degradersConventional small molecule therapeutics work via a drug-induced interference with a protein activity. This limitation to agonistic or antagonistic functions renders about 90% of prot...